{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:24:56Z","timestamp":1773941096258,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.urolonc.2020.06.010","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T01:13:06Z","timestamp":1594343586000},"page":"75.e1-75.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma"],"prefix":"10.1016","volume":"39","author":[{"given":"Xu","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.06.010_bib0001","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2010.12.042","article-title":"European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update","volume":"59","author":"Roupret","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0002","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0003","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.juro.2007.01.030","article-title":"Behavior of urothelial carcinoma with respect to anatomical location","volume":"177","author":"Catto","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0004","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s00428-006-0150-4","article-title":"Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract","volume":"448","author":"Langner","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","article-title":"Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature","volume":"62","author":"Lughezzani","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0006","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1111\/ajco.12155","article-title":"Pathological risk factors in upper urinary tract cancer","volume":"12","author":"Shimamoto","year":"2016","journal-title":"Asia Pac J Clinical Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0007","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1258\/ar.2012.110700","article-title":"Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy","volume":"53","author":"Kim","year":"2012","journal-title":"Acta radiologica (Stockholm, Sweden: 1987)"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0008","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0009","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0010","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0011","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0012","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0014","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0015","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0016","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2020.06.010_bib0017","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1200\/JCO.2018.36.6_suppl.407","article-title":"Results of POUT: a phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)","volume":"36","author":"Birtle","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0018","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0019","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1245\/s10434-013-3349-z","article-title":"Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location","volume":"21","author":"Tanaka","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0020","first-page":"163","article-title":"Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience","volume":"46","author":"Kikuchi","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0021","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.1991.tb15064.x","article-title":"Transitional cell carcinoma of the upper urinary tract: prognostic variables and post-operative recurrences","volume":"67","author":"Krogh","year":"1991","journal-title":"Br J Urol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0022","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00345-011-0709-9","article-title":"Impact of gender on bladder cancer incidence, staging, and prognosis","volume":"29","author":"Fajkovic","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0023","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2016.01.003","article-title":"Prognostic significance of preoperative serum lactate dehydrogenase in upper urinary tract urothelial carcinoma","volume":"14","author":"Zhang","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0025","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.02.010","article-title":"Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy","volume":"33","author":"Shibing","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0027","doi-asserted-by":"crossref","first-page":"e6945","DOI":"10.1097\/MD.0000000000006945","article-title":"Prognostic significance of urothelial carcinoma with divergent differentiation in upper urinary tract after radical nephroureterectomy without metastatic diseases: a retrospective cohort study","volume":"96","author":"Qin","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0028","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0029","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.010_bib0030","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eururo.2012.11.042","article-title":"Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials","volume":"63","author":"Sonpavde","year":"2013","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920302775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920302775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:20:51Z","timestamp":1761042051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920302775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1078143920302775"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}